Therapeutic Targeting Of Il-7r Alpha Signaling Pathways In All Treatment

Increased understanding of pediatric acute lymphoblastic leukemia (ALL) pathobiology has led to dramatic improvements in patient survival. However, there is still a needto developtargeted therapies toenable reduced chemotherapy intensity and to treat relapsed patients. The interleukin-7 receptor alpha ( IL-7R alpha) signaling pathways areprime therapeutic targetsbecause these pathways harbor genetic aberrations in both T-cell ALL and B-cell precursor ALL. Therapeutic targeting of the IL-7R alpha signaling pathways may lead to improved outcomes in a subset of patients.